mL), and suppressed TSH at <0.01 uIU/mL (0.55-4.78 uIU/ mL). TSH-R Ab was elevated at 12.49 IU/L, but TSI bioassay (normal range <140%) was normal (37%). Initial absolute neutrophil count (ANC) was normal, but aspartate transaminase and alanine transaminase were slightly elevated. The patient started CZ at 10 mg/day with a beta-blocker for symptom relief. After 3 weeks on this treatment dose, the patient reported 2 days of sore throat and intermittent fever. She reported no sick contacts, travel history, or taking other medications. Physical examination revealed tachycardia, mild fever (38.6°C), and bilateral submandibular lymph node enlargement. Blood tests revealed ANC of 0 cells/μL. Other tests, including blood, urine, and throat cultures, were within normal limits. Blood chemistry, including a liver function test, was normal. CZ-induced agranulocytosis was strongly suspected based on negative findings for other causes. Fever subsided after the second day of administration.
Based on a strong suspicion of ATD-induced agranulocytosis, CZ was immediately halted. Broad spectrum antibiotics were administered, and granulocyte colony-stimulating factor (G-CSF) was injected subcutaneously. ANC remained at 0 cells/μL for the first 4 days despite administering 300 mcg/ day G-CSF. ANC increased to 20 cell/μL over the next 2 days and then decreased to 0 cell/μL on days seven and eight, after which it increased. Follow-up testing after 14 days off CZ showed ANC at 2250 cell/μL. G-CSF was stopped at day 14. For the management of hyperthyroidism, we administered 27 g/day of cholestyramine, KI solution 5 mL t.i.d., and a beta-blocker while ATD was stopped. The patient was discharged on day 16 without development of any further complications. At discharge, her ANC was 1790 cell/μL. One month after development of agranulocytosis, ANC had recovered to within the normal range. After recovery, she was administrated 131 I radioiodine for definitive treatment of GD.
| DISCUSSION
MZ and CZ are the standard therapies for GD. Both drugs inhibit the enzyme thyroperoxidase, which acts in thyroid hormone synthesis. CZ is a precursor of MZ and is widely used in Korea. CZ is rapidly converted to MZ in serum. MZ and CZ have identical mechanism of action and are considered identical. 2 Propylthiouracil (PTU) was used for treating GD until serious reports of its hepatotoxic effects were published. PTU is the third most common cause of drug-induced liver transplant in the Unites States.
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Adverse effects are also associated with the use of MZ/ CZ. From minor side effects (pruritus and urticaria) to major adverse effects (agranulocytosis and even StevensJohnson syndrome), diverse spectrum of side effects has been reported. 6 Agranulocytosis is defined as a granulocyte count <500 cell/μL. 7 It is a rare occurrence, with an incidence from 0.2% to 0.5%, 8 and is usually observed within 3 months after starting ATD. at 120 mg/d. 14 The mechanism of ATD-induced agranulocytosis is unclear. Recently, Hirotoshi et al suggested two possible mechanisms: (1) an immune-mediated process and (2) direct intoxication. 10 Guffy et al 15 reported the presence of complement-dependent IgM antibodies against granulocytes in a patient receiving PTU. Regarding the direct intoxication process, Wall et al 16 demonstrated the existence of circulating antibodies to differentiated granulocytes, monocytes, and myeloid and erythroid progenitor cells. Generally, agranulocytosis caused by immune-mediated processes proceed rapidly, whereas destruction of granulocytes by direct intoxication occurs after a few weeks. 10 In the present case, we observed agranulocytosis 3 weeks after initiation of CZ at 10 mg/d, in a patient who had previously been tolerant of MZ for 72 months. As Guffy et al 15 suggested, immunogenic abnormalities that underlie drug sensitivities and induce direct intoxication may be genetic, and some patients may be more susceptible, as in the present case. The most important lesson from this case is that clinicians must remain vigilant for agranulocytosis from antithyroid drugs regardless of treatment duration or dose.
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